Literature DB >> 16731798

Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells.

M Candolfi1, G Jaita, D Pisera, L Ferrari, C Barcia, C Liu, J Yu, G Liu, M G Castro, A Seilicovich.   

Abstract

Our previous work showed that tumor necrosis factor (TNF)-alpha and FasL induce apoptosis of anterior pituitary cells. To further analyze the effect of these proapoptotic factors, we infected primary cultures from rat anterior pituitary, GH3 and AtT20 cells with first-generation adenoviral vectors encoding TNF-alpha, FasL or, as a control, beta-galactosidase (beta-Gal), under the control of the human cytomegalovirus promoter. Successful expression of the encoded transgenes was determined by immunocytochemistry. Although we observed basal expression of TNF-alpha and FasL in control cultures of anterior pituitary cells, fluorescence-activated cell sorting (FACS) cell cycle analysis showed that the overexpression of TNF-alpha or FasL increases the percentage of hypodiploid lactotropes and somatotropes. Nuclear morphology and TUNEL staining revealed that the cells undergo an apoptotic death process. We detected strong immunoreactivity for TNFR1 and Fas in the somatolactotrope cell line GH3. TNF-alpha, but not FasL, was expressed in control cultures of GH3 cells. The infection of GH3 cells with adenovirus encoding TNF-alpha or FasL increased the percentages of hypodiploid and TUNEL-positive cells. TNF-alpha or FasL immunoreactivity was not observed in the corticotrope cell line AtT20. However, adenovirus encoding TNF-alpha or FasL efficiently transduced these cells and increased the percentages of hypodiploid and TUNEL-positive cells. The expression of beta-Gal was detected in all these cultures but did not affect cell viability. In conclusion, these results suggest that death signaling cascades triggered by TNF receptor 1 (TNFR1) and Fas are present in both normal and tumoral pituitary cells. Therefore, overexpression of proapoptotic factors could be a useful tool in the therapy of pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731798     DOI: 10.1677/joe.1.06594

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS.

Authors:  Silvia S Rodriguez; Maria G Castro; Oscar A Brown; Rodolfo G Goya; Gloria M Console
Journal:  Expert Rev Endocrinol Metab       Date:  2009-07-01

2.  Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.

Authors:  Marianela Candolfi; Kader Yagiz; David Foulad; Gabrielle E Alzadeh; Matthew Tesarfreund; A K M Ghulam Muhammad; Mariana Puntel; Kurt M Kroeger; Chunyan Liu; Sharon Lee; James F Curtin; Gwendalyn D King; Jonathan Lerner; Katsuaki Sato; Yohei Mineharu; Weidong Xiong; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2009-07-01       Impact factor: 12.531

3.  Thyroid hormone antagonizes tumor necrosis factor-alpha signaling in pituitary cells through the induction of dual specificity phosphatase 1.

Authors:  Marina Lasa; Beatriz Gil-Araujo; Marta Palafox; Ana Aranda
Journal:  Mol Endocrinol       Date:  2009-12-23

4.  TNF-α-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas.

Authors:  Zhengzheng Xiao; Qin Liu; Feng Mao; Jun Wu; Ting Lei
Journal:  Int J Mol Sci       Date:  2011-06-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.